Scopus Biopharma Stock Market Value
| SCPS Stock | USD 0.0004 0.00 0.00% |
| Symbol | Scopus |
Scopus Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Scopus Biopharma's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Scopus Biopharma.
| 11/29/2025 |
| 02/27/2026 |
If you would invest 0.00 in Scopus Biopharma on November 29, 2025 and sell it all today you would earn a total of 0.00 from holding Scopus Biopharma or generate 0.0% return on investment in Scopus Biopharma over 90 days. Scopus Biopharma is related to or competes with Orphazyme A/S. Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics t... More
Scopus Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Scopus Biopharma's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Scopus Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0576 | |||
| Maximum Drawdown | 83.33 | |||
| Value At Risk | (33.33) | |||
| Potential Upside | 25.0 |
Scopus Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scopus Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Scopus Biopharma's standard deviation. In reality, there are many statistical measures that can use Scopus Biopharma historical prices to predict the future Scopus Biopharma's volatility.| Risk Adjusted Performance | 0.0599 | |||
| Jensen Alpha | 0.4573 | |||
| Total Risk Alpha | (1.15) | |||
| Treynor Ratio | 0.222 |
Scopus Biopharma February 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0599 | |||
| Market Risk Adjusted Performance | 0.232 | |||
| Mean Deviation | 5.77 | |||
| Coefficient Of Variation | 1508.45 | |||
| Standard Deviation | 14.09 | |||
| Variance | 198.64 | |||
| Information Ratio | 0.0576 | |||
| Jensen Alpha | 0.4573 | |||
| Total Risk Alpha | (1.15) | |||
| Treynor Ratio | 0.222 | |||
| Maximum Drawdown | 83.33 | |||
| Value At Risk | (33.33) | |||
| Potential Upside | 25.0 | |||
| Skewness | 1.21 | |||
| Kurtosis | 6.85 |
Scopus Biopharma Backtested Returns
Scopus Biopharma appears to be out of control, given 3 months investment horizon. Scopus Biopharma owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0597, which indicates the firm had a 0.0597 % return per unit of risk over the last 3 months. By inspecting Scopus Biopharma's technical indicators, you can evaluate if the expected return of 0.75% is justified by implied risk. Please review Scopus Biopharma's Variance of 198.64, coefficient of variation of 1508.45, and Risk Adjusted Performance of 0.0599 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Scopus Biopharma holds a performance score of 4. The entity has a beta of 4.16, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Scopus Biopharma will likely underperform. Please check Scopus Biopharma's jensen alpha and rate of daily change , to make a quick decision on whether Scopus Biopharma's existing price patterns will revert.
Auto-correlation | -0.38 |
Poor reverse predictability
Scopus Biopharma has poor reverse predictability. Overlapping area represents the amount of predictability between Scopus Biopharma time series from 29th of November 2025 to 13th of January 2026 and 13th of January 2026 to 27th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Scopus Biopharma price movement. The serial correlation of -0.38 indicates that just about 38.0% of current Scopus Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.38 | |
| Spearman Rank Test | 0.3 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Scopus OTC Stock Analysis
When running Scopus Biopharma's price analysis, check to measure Scopus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scopus Biopharma is operating at the current time. Most of Scopus Biopharma's value examination focuses on studying past and present price action to predict the probability of Scopus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scopus Biopharma's price. Additionally, you may evaluate how the addition of Scopus Biopharma to your portfolios can decrease your overall portfolio volatility.